BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 20959606)

  • 21. Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells.
    Piazzi M; Bavelloni A; Cenni V; Salucci S; Bartoletti Stella A; Tomassini E; Scotlandi K; Blalock WL; Faenza I
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
    Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
    Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
    Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
    Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
    Zoellner AK; Bayerl S; Hutter G; Zimmermann Y; Hiddemann W; Dreyling M
    Leuk Lymphoma; 2015; 56(12):3393-400. PubMed ID: 26237681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.
    Martín-Sánchez E; Rodríguez-Pinilla SM; Sánchez-Beato M; Lombardía L; Domínguez-González B; Romero D; Odqvist L; García-Sanz P; Wozniak MB; Kurz G; Blanco-Aparicio C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; García JF; Bischoff JR; Piris MA
    Haematologica; 2013 Jan; 98(1):57-64. PubMed ID: 22801959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101.
    Riyahi N; Safaroghli-Azar A; Sheikh-Zeineddini N; Sayyadi M; Bashash D
    Cancer Invest; 2019; 37(7):311-324. PubMed ID: 31412710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
    Stamatkin C; Ratermann KL; Overley CW; Black EP
    Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.
    Park GB; Hur DY; Kim D
    Anticancer Res; 2015 May; 35(5):2699-708. PubMed ID: 25964548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
    Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
    Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idelalisib: Targeting the PI3 Kinase Pathway in Non-Hodgkin Lymphoma.
    Sujobert P; Rioufol C; Salles GA
    Cancer J; 2016; 22(1):12-6. PubMed ID: 26841011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 36. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
    So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
    J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.
    Beer-Hammer S; Zebedin E; von Holleben M; Alferink J; Reis B; Dresing P; Degrandi D; Scheu S; Hirsch E; Sexl V; Pfeffer K; Nürnberg B; Piekorz RP
    J Leukoc Biol; 2010 Jun; 87(6):1083-95. PubMed ID: 20200404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
    Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
    Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemangiopoietin inhibits apoptosis of MO7e leukemia cells through phosphatidylinositol 3-kinase-AKT pathway.
    Zhan M; Han ZC
    Biochem Biophys Res Commun; 2004 Apr; 317(1):198-204. PubMed ID: 15047168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
    Curigliano G; Shah RR
    Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.